Having trouble accessing articles? Reset your cache.

NextCure’s NC318 data shines light on SIGLEC15 as next hot IO target

Phase I data from a cohort of NSCLC patients treated with NextCure’s NC318 suggest the SIGLEC15-targeted mAb could be the next immunotherapy to rival the single agent efficacy of PD-1 and PD-L1 inhibitors.

The data drove shares of NextCure Inc. (NASDAQ:NXTC) up

Read the full 428 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE